Paxlovid (nirmatrelvir-ritonavir) is efficient at stopping hospitalization and dying from COVID-19, however few individuals use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to search out out why. Their survey revealed sufferers had a lack of information of the remedy in addition to misinformation in regards to the remedy (amongst those that have been conscious of it). Particularly:
A majority of respondents (85 %) had no or low consciousness of Paxlovid, together with 31 % who had by no means heard of it. Even amongst those that have been conscious of the drug, many held misperceptions about its effectiveness (39 %), adversarial results (86 %), and requisite timing (61 %) that might result in underuse. Decrease consciousness and misperceptions have been extra widespread amongst medically susceptible and deprived populations who would possibly profit most from Paxlovid entry, together with adults unvaccinated in opposition to COVID-19, these with decrease ranges of training, and Black and Hispanic or Latino adults.
You may learn the total paper right here.
